Edesa Biotech, Inc.

NasdaqCM:EDSA Voorraadrapport

Marktkapitalisatie: US$10.4m

Edesa Biotech Toekomstige groei

Future criteriumcontroles 0/6

Edesa Biotech's earnings are forecast to decline at 32.7% per annum. EPS is expected to grow by 16.6% per annum.

Belangrijke informatie

-32.7%

Groei van de winst

16.6%

Groei van de winst per aandeel

Biotechs winstgroei27.1%
Inkomstengroein/a
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Low

Laatst bijgewerkt20 Aug 2024

Recente toekomstige groei-updates

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Sep 23
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

Sep 07

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Aug 12

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

May 16
Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Apr 18

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27
Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19
Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08
Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

Winst- en omzetgroeiprognoses

NasdaqCM:EDSA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
9/30/2026N/A-14N/AN/A1
9/30/2025N/A-11N/AN/A2
9/30/2024N/A-8N/AN/A2
6/30/2024N/A-7-5-5N/A
3/31/2024N/A-7-6-6N/A
12/31/2023N/A-8-6-6N/A
9/30/2023N/A-8-7-7N/A
6/30/2023N/A-9-11-11N/A
3/31/2023N/A-13-12-12N/A
12/31/2022N/A-16-11-11N/A
9/30/2022N/A-18-12-12N/A
6/30/2022N/A-18-7-7N/A
3/31/2022N/A-17-7-7N/A
12/31/2021N/A-15-14-14N/A
9/30/2021N/A-13-14-14N/A
6/30/20210-12-15-15N/A
3/31/20210-9-13-13N/A
12/31/20200-8-7-7N/A
9/30/20200-6-5-5N/A
6/30/20201-5-5-5N/A
3/31/20201-5-6-6N/A
12/31/20191-4-6-6N/A
9/30/20190-3-5-5N/A
6/30/20190-3-4-4N/A
3/31/2019N/A-2-1-1N/A
12/31/2018N/A-2-1-1N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: EDSA is forecast to remain unprofitable over the next 3 years.

Winst versus markt: EDSA is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: EDSA is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: Insufficient data to determine if EDSA's revenue is forecast to grow faster than the US market.

Hoge groei-inkomsten: EDSA is forecast to have no revenue next year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if EDSA's Return on Equity is forecast to be high in 3 years time


Ontdek groeibedrijven